Noxopharm Ltd
ASX:NOX
Noxopharm Ltd
ASX:NOX
Price:
0.062
AUD
6.9%
Market Closed
Market Cap:
AU$19m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Noxopharm Ltd
ASX:NOX
|
AU |
|
K
|
Kyverna Therapeutics Inc
NASDAQ:KYTX
|
US |
|
Guangdong Kitech New Material Holding Co Ltd
SZSE:300995
|
CN |
|
I
|
Investment and Industrial Development Joint Stock Corp
VN:BCM
|
VN |
|
JBCC Holdings Inc
TSE:9889
|
JP |
|
Rich Capital Holdings Ltd
SGX:5G4
|
SG |
|
Asahi Printing Co Ltd
TSE:3951
|
JP |
|
North Electro-Optic Co Ltd
SSE:600184
|
CN |
|
Qualicorp Consultoria e Corretora de Seguros SA
BOVESPA:QUAL3
|
BR |
|
Toyou Feiji Electronics Co Ltd
SZSE:300302
|
CN |
|
M
|
MariaDB PLC
NYSE:MRDB
|
IE |
|
L
|
Ladun Investment Company SCJSC
SAU:9535
|
SA |
|
Singaraja Putra Tbk PT
IDX:SINI
|
ID |
Multiples-Based Value
The Multiples-Based Value of one
NOX
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 0.062 AUD,
Noxopharm Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOX Multiples-Based Value
LOCKED
Multiples Across Competitors
NOX Competitors Multiples
Noxopharm Ltd Competitors
Noxopharm Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Noxopharm Ltd
ASX:NOX
|
18.1m AUD | 5.3 | -3.3 | -5.3 | -5.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.5B USD | 6 | 88.3 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.3B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.5B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.2B USD | 9.2 | 28 | 21 | 21.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.7B USD | 5.5 | 17.5 | 12.9 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR | 12.4 | 39.8 | 43.2 | 44.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 2.9 | 32.4 | 10.9 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
